Exchange Traded Concepts LLC Has $139,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Exchange Traded Concepts LLC increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 57.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,266 shares of the medical equipment provider’s stock after purchasing an additional 460 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Lantheus were worth $139,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 208 shares during the last quarter. Fidelis Capital Partners LLC acquired a new stake in Lantheus during the 1st quarter worth approximately $34,000. FinTrust Capital Advisors LLC lifted its holdings in Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock worth $41,000 after purchasing an additional 232 shares during the last quarter. Nkcfo LLC acquired a new stake in Lantheus during the 2nd quarter worth approximately $47,000. Finally, UMB Bank n.a. lifted its holdings in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the sale, the president now owns 98,980 shares in the company, valued at $9,540,682.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares in the company, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,981 shares of company stock worth $2,689,156 in the last 90 days. Insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on LNTH shares. Truist Financial dropped their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. B. Riley lifted their price objective on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. JMP Securities dropped their price objective on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Redburn Atlantic started coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. Finally, Leerink Partners lifted their price objective on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Price Performance

Lantheus stock opened at $112.63 on Wednesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The stock has a market capitalization of $7.81 billion, a P/E ratio of 17.20 and a beta of 0.50. The stock has a fifty day moving average of $106.41 and a 200-day moving average of $92.10.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company’s revenue was up 22.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.40 EPS. On average, sell-side analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.